ClinicaliQ Trial Snapshot
- Identification of B Regulatory Cells by Flow Cytometry — Recruiting • Oncology • NCT06876506.
- What is being tested: Development and validation of a flow cytometry-based test to quantify B-regulatory cells (Bregs) in blood samples from allergic patients undergoing immunotherapy treatment.
- Patient eligibility overview: Study includes adults with pollen or insect venom allergies receiving allergen immunotherapy, requiring blood sampling at defined timepoints to measure Breg population changes during treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is; 1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to…
Eligibility Snapshot
- Control cohort - Participants with: * No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms * Negative serological testing for specific IgE to pollens, house dust mite and insect venoms * Patients aged 18 years or older Test cohort: * Participants over the age of 18 years * Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.